TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00842829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Buccal Tablet (FBT)
Description: FBTs were self-administered by participants via the oral mucosa. During the open-label dose titration period, participants used 1 to 4 tablets of the 100 mcg or 200 mcg strength to individually titrate upwards to an effective dose through the range of available strengths (i.e. 100, 200, 400, 600, or 800 mcg). For the open-label treatment and continuation periods, single dose tablets at the effective dose identified during the titration period were used. The maximum dose allowed per breakthrough pain (BTP) episode was 800 mcg. On any single day, participants were not to use FBT for more than 4 BTP episodes.
Study: NCT01523184

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: This is the placebo capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YKP10811 Drug Product Capsule
Description: The drug product, YKP10811, 10 mg under investigation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YKP10811 Drug Product Capsule
Description: The drug product, YKP10811, 20 mg under investigation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YKP10811 Drug Product Capsule
Description: The drug product, YKP10811, 30 mg under investigation
Study: NCT02283086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician Feedback Reporting
Description: The performance feedback reports displayed both individual physicians' statistics as well as their performance compared to anonymized results for the entire group of emergency physicians.
Study: NCT02713594

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Counseling from WTQL
Description: Counseling from the Wisconsin Tobacco Quit Line (WTQL) consisted of 5 proactive calls to the participant to help them successfully quit tobacco use, plus ad hoc calls at the participant's initiation; also, WTQL coaches encouraged participants to see their health care provider to obtain Medicaid-approved smoking cessation medications to help them quit smoking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling from WTQL
Description: Counseling from the Wisconsin Tobacco Quit Line (WTQL) consisted of 5 proactive calls to the participant to help them successfully quit tobacco use, plus ad hoc calls at the participant's initiation; also, WTQL coaches encouraged participants to see their health care provider to obtain Medicaid-approved smoking cessation medications to help them quit smoking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial incentive to participate
Description: Participants in the Incentive condition received $30 per call for up to five WTQL calls taken; in addition, Incentive condition participants received $40 for producing biochemical evidence of abstinence at the 6-month follow-up visit. (Note that participants in both the Control condition and the Incentive condition received $40 for completing the baseline biochemical smoking status assessment visit and $40 for completing the 6-month follow-up biochemical smoking status assessment visit.) Compensation was in the form of prepaid Visa gift cards mailed approximately 2-4 weeks after the point of contact.
Study: NCT03493282

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Treatment- CT1812 100 mg
Description: CT1812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Treatment- CT1812 300 mg
Description: CT1812

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT02125409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: One tablet of Adiro 100 mg will be administered daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: One tablet of Adiro 100 mg will be administered daily for 7 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Screening colonoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Screening colonoscopy
Study: NCT01360658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins
Description: Single administration of 2 g/kg intravenous immunoglobulins over 2 days
Study: NCT02725047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Crushed ice (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton)
Study: NCT02725047

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Sand
Description: Sand (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the sand bags, they will be fixed with an elastic bandage (compression). Also, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton) to mimic the experimental group.
Study: NCT02888548

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: botulinum toxins (Dysport°) alone
Description: botulinum toxins (Dysport°) alone
Study: NCT03767309

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronally advanced flap with abrasive de-epithelized graft.
Description: SCTG will be harvested from the palate by abrasive de-epithelialization of palatal graft involves removing the epithelium of the selected area with a high-speed hand piece and diamond bur

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronally advanced flap with de-epithelized graft.
Description: SCTG will be harvested from the palate by abrasive de-epithelialization of palatal graft involves removing the epithelium of the selected area with a blade
Study: NCT02432924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instant + Multidimensional Physical Activity Feedback
Study: NCT04606810

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: multidisciplinary educational intervention
Description: At randomization, participants in arm 1 received the educational DVD with the instruction to review its contents within the next two weeks. Between 2 and 4 weeks after randomization, reinforcement teleconferences were done in small groups of 10 participants maximum per session with every participant who mentioned having watched the DVD. Each participant attended only to one teleconference. Usual care consisted in regular follow-up with the treating rheumatologist and possibility of asking questions of the rheumatology nurse by phone.

Intervention type: OTHER
Group type: OTHER
Intervention: multidisciplinary educational intervention
Description: At randomization, participants in arm 1 received the educational DVD with the instruction to review its contents within the next two weeks. Between 2 and 4 weeks after randomization, reinforcement teleconferences were done in small groups of 10 participants maximum per session with every participant who mentioned having watched the DVD. Each participant attended only to one teleconference. Usual care consisted in regular follow-up with the treating rheumatologist and possibility of asking questions of the rheumatology nurse by phone.
Study: NCT04118127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2mg conventional tablet, once-weekly tablets
Description: In each cohort, subjects will receive a brexpiprazole 2 mg conventional tablet on Day 1of Period 1, the QW formulation on Day 1 of Period 2 and 3, as single and multiple dose in a fasted state.
Study: NCT02134340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [I-124]-CPD-1028 Injection
Description: A single intravenous dose of \[I-124\]-CPD-1028 Injection will be given at Visit 2 (within 21 days of screening Visit 1), and may be followed by whole body PET/CT imaging approximately 3 hours post-injection. PET/CT imaging will occur at Visit 3 (2-3 days after Visit 2) and Visit 4 (5-7 days after Visit 2). PET/CT imaging may also occur at Visit 5 (16-18 days after Visit 2). Visit 6 (28 +/- 2 days after Visit 2) is a follow-up telephone call for a post-treatment safety assessment. At Visits 2-5, whole body biodistribution and tumour uptake will be assessed. At all visits, safety will be assessed.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPD-1061
Description: \[Optional\] An intravenous dose of 0.4, 1.4 or 6 mg/kg of body weight of CPD-1061 may be given 1-2 hours prior to injection of \[I-124\]-CPD-1028 at Visit 2. The decision to use CPD-1061 and the dose amount is based on an adaptive design and is dependent on interim reviews of imaging data.
Study: NCT00830479

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anti-reflux surgery
Description: Open ureteroneocystostomy for correction of vesicoureteral reflux

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic injection
Description: Endoscopic injection of dextranomer/hyaluronic acid gel (Deflux) for correction of vesicoureteral reflux
Study: NCT04557189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-951
Description: TAK-951 SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Placebo
Description: Ondansetron placebo-matching IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-951 Placebo
Description: TAK-951 placebo-matching SC injection
Study: NCT03802045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle
Description: Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used.
Study: NCT01997827

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: metal-ceramic RBFDP
Description: Rehabilitation of tooth loss with a metal-ceramic RBFDP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: all-ceramic RBFDP
Description: Rehabilitation of tooth loss with an all-ceramic RBFDP
Study: NCT01200758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab SC
Description: First cycle of rituximab IV infusion (375 mg/m\^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab IV
Description: Eight cycles of rituximab IV infusion (375 mg/m\^2; rituximab induction) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\^2) once every 8 weeks for 24 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Eight cycles of cyclophosphamide (750 mg/m\^2 IV) administered every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Eight cycles of cyclophosphamide (750 mg/m\^2 IV) administered every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Eight cycles of doxorubicin (50 mg/m\^2 IV) administered every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Eight cycles of doxorubicin (50 mg/m\^2 IV) administered every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Eight cycles of doxorubicin (1.4 mg/m\^2 IV) administered every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Eight cycles of doxorubicin (1.4 mg/m\^2 IV) administered every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone/Prednisolone
Description: Eight cycles of prednisone/prednisolone (100 mg/day or 40 mg/m\^2/day IV/orally) administered Days 1 to 5 of every 21 days cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone/Prednisolone
Description: Eight cycles of prednisone/prednisolone (100 mg/day or 40 mg/m\^2/day IV/orally) administered Days 1 to 5 of every 21 days cycle.
Study: NCT01638546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT03335137

Intervention type: DIAGNOSTIC_TEST
Intervention: Drug Level Monitoring
Description: Free (unbound) drug concentration 1 hour, 4 hours and 7.5 hours after primary load of piperacillin/tazobactam on day 1 and day 3 after admission

Intervention type: DIAGNOSTIC_TEST
Intervention: Drug Level Monitoring
Description: Free (unbound) drug concentration 1 hour, 4 hours and 7.5 hours after primary load of piperacillin/tazobactam on day 1 and day 3 after admission
Study: NCT01554319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB010
Description: Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).~Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board.~Dose group A : 5 mg hgd40/2 mL; Dose group B: 10 mg hgd40/2 mL; Dose group C: 20 mg hgd40/2 mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (phosphate-buffered saline)
Description: Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).~Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board.
Study: NCT04050215

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-labeled PSMA-11
Description: Given IV
Study: NCT03802045

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needle
Description: Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle
Description: Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used.
Study: NCT04050215

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02461251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotational Thromboelastometry (ROTEM)
Description: A Point-of-care blood coagulation test tool is used to guide the treatment of major obstetric bleeding.
Study: NCT03802045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle
Description: Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Needle
Description: Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Adhesive Moxa
Description: In the placebo group an adhesive moxa will be placed on each acupoint and the needle will be inserted over it.
Study: NCT00910169

Intervention type: OTHER
Intervention: inpatient treatment
Description: Hospitalisation modalities are described but are naturalistic
Study: NCT03414294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-755 Part A (SAD)
Description: Single ascending dose (SAD). There will be 7 cohorts in the Part A. Three quarters of subjects will receive K-755 tablet orally in a double-blind fashion.
Study: NCT02888548

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: botulinum toxins (Dysport°) alone
Description: botulinum toxins (Dysport°) alone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined
Description: orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined
Study: NCT00511823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casopitant
Description: The doses of casopitant will be comprised of 150 mg (one 150 mg tablet) and 50 mg (one 50 mg tablet). Casopitant will be taken with 240 milliliters (mL) of water on an empty stomach following at least 2 hour fast.
Study: NCT03414294

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Part A (SAD)
Description: Single ascending dose (SAD). In Part A, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
Study: NCT00511823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casopitant
Description: The doses of casopitant will be comprised of 150 mg (one 150 mg tablet) and 50 mg (one 50 mg tablet). Casopitant will be taken with 240 milliliters (mL) of water on an empty stomach following at least 2 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casopitant
Description: The doses of casopitant will be comprised of 150 mg (one 150 mg tablet) and 50 mg (one 50 mg tablet). Casopitant will be taken with 240 milliliters (mL) of water on an empty stomach following at least 2 hour fast.
Study: NCT02888548

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined
Description: orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined
Study: NCT01801150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP nasal treatment
Description: Treatment with titred CPAP nasal during the nighttime
Study: NCT02418195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: IV infusion of ketamine 0.5mg/kg at a rate of 40mL over 40 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: IV infusion of ketamine 0.5mg/kg at a rate of 40mL over 40 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: IV infusion of ketamine 0.5mg/kg at a rate of 40mL over 40 minutes
Study: NCT01512953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 30 mg once a day
Study: NCT01549964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasiglifam (TAK-875)
Description: Fasiglifam (TAK-875) tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasiglifam (TAK-875)
Description: Fasiglifam (TAK-875) tablets
Study: NCT00511823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolasetron
Description: The dose of oral dolasetron will be comprised of 100 mg (one 100 mg tablet or two 50 mg tablets). Dolasetron will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
Study: NCT01675063

Intervention type: DEVICE
Group type: OTHER
Intervention: Retia Non-Invasive Sensors
Description: Three adhesive sensor patches (similar to ECG patches) will be placed on the chest and a sensor similar to a pulse oximeter will be placed on the toe. The sensors will be connected to an electrical amplifier that produces a waveform.
Study: NCT01296100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (nutrition)
Description: The 200 study participants of this arm will first receive 6 months of Nutritional counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
Study: NCT01549964

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching tablets
Study: NCT01969812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evie Slow-release Insemination Device
Study: NCT01296100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (physical activity)
Description: The 200 study participants of this arm will first receive 6 months of physical activity counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
Study: NCT01969812

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Intrauterine Insemination
Study: NCT01824186

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SILC
Description: Underwent single-incision laparoscopic cholecystectomy
Study: NCT01525459

Intervention type: PROCEDURE
Intervention: Glioma resection
Description: Patients will be treated with the standard surgical therapy - glioma resection.

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood samples used for measuring studied parameters will be taken within 10 days before surgery, one day after surgery and once more within 10 days following the operative procedure.
Study: NCT02771366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fermented Papaya Preparation
Description: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fermented Papaya Preparation
Description: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Granulated Sugar
Description: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Granulated Sugar
Description: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
Study: NCT02776124

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Healing Elements,Methuselah Medical Technology
Description: ONS group will receive Healing Elements ONS everyday during CRT